Clene INC

Clene Inc. has deferred debt payments and received shareholder approval to increase its 2020 Stock Plan by 1 million shares.

Clene Inc. announced a second amendment to its senior secured convertible promissory notes, extending the maturity date and deferring payments, alongside positive updates on its CNM-Au8 program for ALS, targeting a Q3 2026 NDA submission.

Clene Inc. has priced an underwritten offering of 1,000,000 shares of common stock at $7.00 per share to raise approximately $6.4 million in net proceeds.

Clene Inc. announced it will file an accelerated approval New Drug Application (NDA) for its ALS treatment, CNM-Au8, following a successful meeting with the FDA.

Clene Inc. announced its full year 2025 financial results and provided updates on its CNM-Au8 programs, including an upcoming FDA meeting for ALS accelerated approval pathway.

Clene Inc. outlines key regulatory and clinical milestones for its lead drug candidate, CNM-Au8, in 2026, alongside an extended operating capital runway.

Clene Inc. reports Q1 2026 results, highlighting progress in ALS and MS drug development, while facing ongoing financial challenges and a going concern assessment.

Clene Inc. reported a reduced net loss in Q3 2025 and advanced its CNM-Au8 clinical programs for ALS and MS, but faces substantial doubt about its ability to continue as a going concern.

Clene Inc. reported a reduced net loss in Q2 2025, while continuing to advance its lead drug candidate CNM-Au8 for ALS and MS, despite ongoing liquidity concerns and internal control weaknesses.

Clene Inc. reports a net loss of $751,000 for Q1 2025, provides updates on its clinical programs, and acknowledges substantial doubt about its ability to continue as a going concern.

Clene Inc. reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and a recent capital raise, while also acknowledging substantial doubt about its ability to continue as a going concern.

Clene Inc. released its second quarter 2024 financial results, highlighting ongoing clinical trial progress and a recent reverse stock split.

Clene Inc. reports strong clinical data for its lead drug candidate CNM-Au8 in ALS, paving the way for an accelerated FDA approval pathway by mid-2026, despite ongoing financial challenges.

Clene Inc. details its 2024 financial results and provides an update on its regulatory strategy for CNM-Au8, its lead drug candidate for ALS.

Clene Inc.'s annual 10-K filing provides a comprehensive overview of the company's capital structure, outstanding warrants, and financial position, highlighting its focus on developing novel nanotherapeutics.

Clene Inc. Chief Science Officer Mark Mortenson received a stock option grant for 45,000 shares.

Clene Inc. reports the grant of 65,000 stock options to President & CEO Robert Etherington.

Clene Inc. Chief Financial Officer Morgan R. Brown reports the grant of 15,000 stock options with an exercise price of $5.53.

Director Vallerie McLaughlin was granted stock options for 3,564 shares of Clene Inc. common stock on May 21, 2026.

Director Arjun Desai was granted 3,658 stock options in Clene Inc. as part of the company's 2020 Stock Plan.

Director Alison Mosca was granted 4,361 stock options in Clene Inc. as part of the company's 2020 Stock Plan.

Clene Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Clene Inc. is holding its 2025 Annual Meeting of Stockholders to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the company's stock plan.

Clene Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Clene Inc. is asking stockholders to vote on proposals including increasing authorized shares, a reverse stock split, director elections, auditor ratification, and executive compensation at its upcoming annual meeting.

Empery Asset Management, LP, through its managed funds, has acquired a beneficial ownership of 916,532 shares, representing 7.17% of Clene Inc.'s common stock, as of June 30, 2026.

Investor Chidozie Ugwumba has filed a Schedule 13G reporting a 9.7% beneficial ownership stake in Clene Inc. common stock.

Alison Mosca has filed an amended Schedule 13G reporting a 13% beneficial ownership stake in Clene Inc. common stock.

Chidozie Ugwumba has filed an amendment to his Schedule 13G, reporting beneficial ownership of 1,915,650 shares of Clene Inc. common stock.

Vivo Opportunity Fund Holdings and related entities have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Clene Inc.

AWM Investment Company, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 4.7% of Clene Inc.'s common stock.